tradingkey.logo

Lilly's Oral Glp-1, Orforglipron, Showed Compelling Efficacy And A Safety Profile Consistent With Injectable Glp-1 Medicines, In Complete Phase 3 Results Published In The New England Journal Of Medicine

ReutersJun 21, 2025 1:15 PM

- Eli Lilly and Co LLY.N:

  • LILLY'S ORAL GLP-1, ORFORGLIPRON, SHOWED COMPELLING EFFICACY AND A SAFETY PROFILE CONSISTENT WITH INJECTABLE GLP-1 MEDICINES, IN COMPLETE PHASE 3 RESULTS PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE

  • ELI LILLY AND CO - ORFORGLIPRON LOWERS A1C BY 1.3% TO 1.6% IN PHASE 3 TRIAL

  • ELI LILLY AND CO - REMAINS ON TRACK TO SUBMIT ORFORGLIPRON FOR WEIGHT MANAGEMENT BY END OF YEAR

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI